Indeed, overexpression of LIFR sensitized PLC/PRF/5 cells to erastin or sorafenib, which could be reversed by co-treatment with liproxstatin-1, DFO, or purified LCN2 protein (Supplementary Fig. 8c), indicating that LIFR sensitizes liver cancer cells to ferroptosis inducers through iron and LCN2. Here, LCN2 is linked to liver cancer.